Healthcare Stocks: Analysts Diverge on Amylyx, Moderna, and Merck
Healthcare stocks have been drawing attention from analysts lately, with opinions varying on several prominent names. Joseph Thome from TD Cowen remains bullish on Amylyx Pharmaceuticals Inc (AMLX), reiterating a Buy rating and a price target of $42.75, which represents a 42.9% upside from the current share price.
However, not all analysts are in agreement. Jessica Fye from J.P. Morgan has maintained a Sell rating on Moderna (MRNA) with a price target of $40.00, citing concerns that may lead to reduced sales. The company's shares closed last Wednesday at $129.75.
Meanwhile, Chris Schott from J.P. Morgan has upgraded Merck & Company (MRK) to Buy with a $152.00 price target, although the current analyst consensus suggests a -5.7% downside from current levels.